TP53 and cancer: We performed mutational analyses for the common and cancer-relevant mutations in the genes KRAS and TP53. Mutational analysis (18 N1 primary tumors and 18 matched lymph node metastases) revealed mutations of TP53 in six samples (19%) and mutations of KRAS in two samples (6%).